LIPOSOMAL CISPLATIN IN CANCER PATIENTS WITH RENAL FAILURE by Stathopoulos, George P et al.
Stathopoulos et al                  Journal of Drug Delivery & Therapeutics; 2012, 2(3): 106-109    106 
© 2011, JDDT. All Rights Reserved                                      ISSN: 2250-1177                                     CODEN: JDDTAO 
Available online at http://jddtonline.info 
RESEARCH ARTICLE 
LIPOSOMAL CISPLATIN IN CANCER PATIENTS WITH RENAL FAILURE 
 
*Stathopoulos P. George, Rigatos Sotiris, Stathopoulos John, Batzios Spyros  
First Oncology Clinic, Errikos Dunant Hospital, Athens Greece-11526 
*Corresponding Author’s E-mail: dr-gps@ath.forthnet.gr, Telephone: + 30-210-7752600, Fax: + 30-210-7251736 
Received 03 April 2012; Revised 30 April 2012; Accepted 09 May 2012, Available online 15 May 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Cytotoxic chemotherapy remains the main treatment for 
malignant tumors. Renal failure is one of the serious 
adverse reactions caused when chemotherapeutical agents 
are admin istered, since the majority of anticancer drugs 
are excreted through the kidneys. When the 
creatinine/glomerular filtrat ion data (GFR) is higher than 
normal, chemotherapy involving almost all cytotoxic 
agents is avoided, or the dosage is reduced. The main  
agent accompanied by renal failure is cisplatin (CDDP);  it  
has been in use for over 30 years and has  been shown to 
be quite an effective agent in a great number of 
malignancies, such as lung, ovarian, head and neck, 
urethral and testicular cancers. 
1-9
 Cisplatin is one of the 
most important anticancer drugs with respect to 
effectiveness, but its toxicity is often an inhibitory factor. 
The main side effect is  renal toxicity (renal failure). Other 
adverse reactions are nausea/vomit ing, fatigue and 
neurotoxicity. 
10-13
 
Over the last decades, there has been an extensive effort 
to substitute other agents for CDDP. The cisplatin 
analogue, carboplatin, has been the drug main ly used, 
instead of cisplatin, for several malignant tumors . 
Taxanes (paclitaxel, docetaxel), gemcitabine and 
vinorelbine have also been tested in several malignancies 
such as non-small-cell lung cancer (NSCLC) and ovarian 
cancer. With the aforementioned agents, renal toxicity 
was avoided but other side effects such as myelotoxicity 
were observed. None of these drugs, however, were better 
than or equal to cisplatin in effectiveness.
14-20
  
Liposomal cisplatin is new formulat ion of cisplatin which 
was produced some years ago. The main scope of this 
new agent was to reduce the nephrotoxicity caused by 
cisplatin, to avoid other adverse reactions and certainly to 
be effective. Up until now, there have been more than 16 
studies (preclin ical and clinical) published on liposomal 
cisplatin (lipoplatin). It has been tested in pancreatic 
cancer, in NSCLC, in breast and in head and neck 
cancers. In the majority of tumors tested, it has been as 
equally effective as cisplatin and much less toxic. 
21-28
 A 
recent study examined the effectiveness of lipoplatin  
versus cisplatin, each combined with paclitaxel, in  
adenocarcinoma of the lungs. It was found that the 
response rate was statistically significantly higher, in  
favour of lipoplatin Arm. 
29
 
The primary object ive of the present study was to 
investigate the administration of lipoplatin in patients 
with renal insufficiency and secondly, to determine the 
response of patients with bladder cancer, the majority of 
whom received the present treatment as first-line therapy.  
MATERIALS AND METHODS  
Eligibility criteria 
Patients >18 years of age with a histologically- or 
cytologically-confirmed d iagnosis of malignant disease, 
who were pretreated or who were chemotherapy- and 
radiotherapy-naïve, were enrolled in the study. Other 
elig ibly criteria included a World Health Organisation 
(WHO) performance status (PS) of 0-2, life expectancy of 
at least 3 months, adequate bone marrow reserve 
(granulocyte count 1500μl-1, platelet count 120000/μl-1), 
normal liver function and normal cardiac function with no 
history of clinically unstable angina pectoris or 
myocardial infarction or congestive heart failure within  
the 6 months prior. Patients with central nervous system 
involvement were elig ible if they were asymptomat ic. 
Patients with active infection, malnutrition or a second 
primary tumor were excluded from the study. Having had 
the experience from previous studies  that liposomal 
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cisplatin causes no renal toxicity, patients with increased 
blood urea and with serum creatinine concentration >1.6-
4mg/dl, were enrolled.  
The study was approved by our institutional review board 
and all patients gave their written informed consent to 
participate. 
Treatment plan  
All patients were treated on an outpatient basis. Five 
patients were init ially treated with lipoplatin  monotherapy 
once every 2 weeks at a dose of 150-200 mg/m
2
. Upon 
finding that no side effects  were observed and there was 
no increase in serum creatin ine, we started the treatment 
in combination with gemcitabine at a dose 1000 mg/m
2
, 
for the patients with bladder cancer. The treatment was 
repeated every 2 weeks. Lipoplat in was infused for 8 
hours and gemcitabine for 90 minutes; lung cancer 
patients received paclitaxel at a dose of 175 mg/m
2
 for 3 
hours, and lipoplatin as above; patients with 
gastrointestinal tract cancer received 700 mg/m
2
 of 5-
fluorouracil (5-FU) and 200 mg of leucovorin, for 2 hours 
and lipoplatin as above. Premedication involved 
dexamethasone (8 mg) and both H1 and H2 receptor 
antagonists to prevent hypersensitivity reactions. All 
agents were given on day 1. Dose adjustment criteria 
were based on hematological and renal parameters. In 
cases of grade 3 and 4 febrile neutropenia, we decided we 
would reduce all drug doses by 25% in the subsequent 
cycles and rhG-CSF was then to be admin istered. 
Toxicities were graded according to the WHO guidelines . 
30
 
Pretreatment evaluation included medical history and 
physical examination, full blood count including 
differential leukocyte and platelet counts, a standard 
biochemical profile, electrocardiogram, X-rays of the 
chest, ultrasound of the upper abdomen and computed 
tomography (CT) scans of the chest, upper and lower 
abdomen. Additional imaging studies were performed  
upon clinical indication. Full blood counts with 
differential were performed weekly. In cases of grade 3 
and 4 neutropenia or thrombocytopenia, full blood counts 
were to be evaluated daily. 
A detailed medical and physical examination was 
completed before each course of treatment (once every 2 
weeks), in o rder to document the symptoms of the disease 
and treatment toxicit ies. CT scans were performed every 
3 cycles (once every 6 weeks). 
Definition for response 
For the assessment of response, we used imaging-based 
evaluation. A complete response (CR) was considered to 
be the disappearance of all measurable disease confirmed  
at 4 weeks at the earliest; a partial response (PR), a 30% 
decrease, also confirmed at 4 weeks at the earliest. In  
stable disease (SD), neither the PR nor the progressive 
disease (PD) criteria were met; PD was considered to be a 
20% increase of tumor burden and no CR, PR or SD 
documented before increased disease. Response data were 
based on the response evaluation criteria in solid tumors 
(RECIST). 
31
 A two-step deterioration in performance 
status, a >10% loss in pretreatment weight or increasing 
symptoms did not by themselves constitute progression of 
the disease; however, the appearance of these complaints 
was followed by a new evaluation of the extent of the 
disease. All responses had to be maintained for at least 4 
weeks and be confirmed by an independent panel of 
radiologists. 
Statistical design 
Simon’s two stage minimax design was used for 
calculation of the sample size. The significance level was 
set to be 5% and the power 90%. Low response 
probability was set to be 20% and the level of useful 
activity 40%. In the first stage, 20 patients were enro lled  
in the study. If 5 or fewer responses had been observed, 
then the study would have been terminated. Otherwise, if 
more than 5 responses were observed, another 20 patients 
would be recruited for a maximum sample size of 40 
patients.  
RES ULTS  
From June 2006 till August 2011, 42 patients were 
enrolled in this one-clinic trial. All were evaluable for 
toxicity and response. The 16 patients with bladder cancer 
had renal insufficiency; 14 of these patients received 
lipoplatin and gemcitabine treatment as a first-line 
chemotherapy and 2 as second-line therapy. Sixteen other 
patients with NSCLC (14 with adenocarcinoma, 2 with 
squamous cell carcinoma) received lipoplatin plus 
paclitaxel as second- or third-line treatment. The 10 
patients with gastrointestinal cancer received lipoplatin-5-
FU-leucovorin as second-line or third-line treatment. 
There were 40 males and 2 females  (median age 65y 
range 49-84y). Fourteen patients with bladder cancer had 
limited disease, whereas the remain ing 28 enro lled  
patients had advanced (Table 1). At the end of the study, 
11 patients were still alive. 
Table 1: Patients’ characteristics  
 n % 
Patients enrolled  42 100 
Patients evaluable 42 100 
Gender  
Male  40 95.24 
Female  2 4.76 
Age (Years) 
Median  65 
Range 49-84 
Disease stage 
Limited 14 33.33 
Advanced 28 66.67 
Histology   
Adenocarcinoma/NSCLC 14 33.33 
Squamous cell 
carcinoma/NSCLC 
2 4.76 
Bladder cancer 16 38.10 
Gastrointestinal tract 
cancer 
10 23.81 
Performance status (WHO) 
0 17 40.48 
1 20 47.62 
2 5 11.90 
NSCLC, non-small-cell lung cancer; WHO (World 
Health Organization) 
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Two hundred and two chemotherapy cycles were 
administered (median 6 cycles, range 2-12). Twelve 
cycles were given to one patient during two different time 
periods. Treatment was delayed for one week in 4 
patients; this delay was due to non-renal toxicity i.e. to 
the myelotoxicity produced by the second cytotoxic 
agent. There was no need to reduce the dose of lipoplatin  
but only that of the second cytotoxic agent, by 25%. At 
the time of analysis , 11 patients (26.19%) were still alive. 
The cause of death for the remaining patients was the 
disease (mainly NSCLC), and heart attack or brain  
metastasis.  
Response to treatment and survival  
Survival was evaluated on an intention-to-treat basis. 
There were 5 (11.9%) complete responses out of the 42 
patients; all five responders had bladder cancer. The 
evaluation was done by bladder endoscopy and CT scan. 
Out of the total number of 16 bladder cancer patients the 
percentage of CR was 31.25%. A partial response was 
achieved by 15 patients, 8 of whom had bladder cancer 
and 7 who had tumors at other sites). Fourteen (33.33%) 
patients had stable disease, 3 of whom had bladder 
cancer. No response was observed in 8 (19.05%) patients 
(Table 2). The median duration of response was in total 7 
months (range 3-11 months). Of the 16 patients with 
bladder cancer the median duration of response was 12 
months (range 4-18 months). One patient with bladder 
cancer who had achieved a complete response, had a 
tumor recurrence after 12 months; he survived for 48 
months and died of a heart attack.  
Table 2: Response rate 
Response n Site n (%) 
Complete response 5 Bladder 5 (11.9) 
   
Partial response 15 Bladder 8 (19.05) 
NSCLC 2 (4.76) 
GI t ract 5 (11.9)  
   
Stable disease 14 Bladder 3 (7.14) 
NSCLC 6 (14.29)  
GI t ract 5 (11.9)  
   
No response 8 NSCLC 8 (19.05) 
NSCLC, non-small-cell lung cancer; GI, 
gastrointestinal 
Toxicity 
All 42 patients were evaluable for toxicity. The treatment 
caused no renal toxicity; there was no increase in blood 
urea and serum creatinine and in some patients there was 
a reduction in these levels. In 10/16 patients with bladder 
cancer, the blood urea and serum creatin ine levels 
decreased, towards normal levels; this reduction was 
observed in these patients who had had a urination 
obstruction, which after treatment returned to normal. 
Grade 1-2 nausea/vomit ing was observed in 8 (19.05%) 
patients. Myelotoxicity was observed in 12 (28.57%) 
patients; this was attributed to the second agent given in 
combination with lipoplatin. Grade 1-2 anemia was 
observed in half of the patients. Grade 1-2 peripheral 
neuropathy was observed in 13 patients who received 
paclitaxel as the second agent. Mild fatigue was also 
observed in the majority of patients (Table 3).  
 
Table 3: Toxicity  
Adverse Reactions Grade 1-2 
n 
% 
Renal failure*  - 0.00 
Nausea/Vomit ing 8 19.05 
Myelotoxicity  12 28.57 
Anemia 21 50.00 
Fatigue 25 59.52 
Peripheral neuropathy 13 30.95 
* None of the 42 patients had an increase in blood 
urea or serum creatin ine 
DISCUSS ION  
Liposomal cisplatin (lipoplatin ) is a new agent which  
could become a substitute for cisplatin. There are more 
than 16 trials concerning lipoplatin and it has shown 
equal effectiveness to cisplatin and a better response rate 
with a statistically significant difference (lipoplatin versus 
cisplatin) in adenocarcinoma of the lungs. 
32
 The most 
important parameter with regard to lipoplatin and part of 
its effectiveness is the lack of adverse reactions: in  
particular, there is no renal toxicity. Th is is due to the low 
excretion of the drug, through the kidneys (40% renal 
excretion in 3 days). 
32
 It is not only this lack of renal 
toxicity but the fact that one can infuse this agent for 8 
hours in patients who already have renal toxicity. There 
are quite a number of patients with blood urea and serum 
creatinine at abnormally high levels where the 
administration of anticancer drugs is impossible with the 
proper (maximum tolerated dose); common treatment 
involves a combination of anticancer agents in order to 
achieve a better response. Lipoplatin may favorably be 
considered as the treatment solution for cancer patients 
with renal insufficiency. To date, the trials on lipoplatin 
have shown that it can be used as a substitute for cisplatin 
in adenocarcinoma of the lungs, in pancreatic and bladder 
cancer; in the future, it might be administred for other 
tumors, such as ovarian cancer, gynaecological 
malignancies, esophageal and gastric cancers. 
In the present study, lipoplatin has shown effectiveness 
without toxicity problems in patients with renal failure. It  
has been tested in NSCLC, in gastrointestinal and in 
bladder cancer. Future trials may confirm the present data 
and be a cause for courage for certain groups of cancer 
patients. 
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